Rituximab is safe and effective in the treatment of patients with non-Hodgkin’s lymphoma (NHL). Rituximab is generally well-tolerated. Its major adverse effects are infusion related and include fever, chills, dyspnea and hypotension. Dyspnea is a frequent complaint in NHL patients, and is often
No takes yet. Share an insight, caveat, or question.
Nieuwenhuizen et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: